336 related articles for article (PubMed ID: 27262709)
61. Disease Assessments in Patients with Glioblastoma.
Phillips KA; Kamson DO; Schiff D
Curr Oncol Rep; 2023 Sep; 25(9):1057-1069. PubMed ID: 37470973
[TBL] [Abstract][Full Text] [Related]
62. Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
Nagpal S; Recht CK; Bertrand S; Thomas RP; Ajlan A; Pena J; Gershon M; Coffey G; Kunz PL; Li G; Recht LD
J Neurooncol; 2015 Jun; 123(2):277-82. PubMed ID: 25935109
[TBL] [Abstract][Full Text] [Related]
63. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
[TBL] [Abstract][Full Text] [Related]
64. Radiology: criteria for determining response to treatment and recurrence of high-grade gliomas.
Lucas J; Zada G
Neurosurg Clin N Am; 2012 Apr; 23(2):269-76, viii. PubMed ID: 22440870
[TBL] [Abstract][Full Text] [Related]
65. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management.
Sturm D; Pfister SM; Jones DTW
J Clin Oncol; 2017 Jul; 35(21):2370-2377. PubMed ID: 28640698
[TBL] [Abstract][Full Text] [Related]
66. MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.
Aquino D; Gioppo A; Finocchiaro G; Bruzzone MG; Cuccarini V
J Immunol Res; 2017; 2017():5813951. PubMed ID: 28512646
[TBL] [Abstract][Full Text] [Related]
67. [The treatment of adult glioma is multiphasic].
Mäenpää HO
Duodecim; 2010; 126(14):1669-75. PubMed ID: 20804085
[TBL] [Abstract][Full Text] [Related]
68. Bevacizumab for the treatment of high-grade glioma.
Khasraw M; Simeonovic M; Grommes C
Expert Opin Biol Ther; 2012 Aug; 12(8):1101-11. PubMed ID: 22663137
[TBL] [Abstract][Full Text] [Related]
69. Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group.
Alexander BM; Brown PD; Ahluwalia MS; Aoyama H; Baumert BG; Chang SM; Gaspar LE; Kalkanis SN; Macdonald DR; Mehta MP; Soffietti R; Suh JH; van den Bent MJ; Vogelbaum MA; Wefel JS; Lee EQ; Wen PY;
Lancet Oncol; 2018 Jan; 19(1):e33-e42. PubMed ID: 29304360
[TBL] [Abstract][Full Text] [Related]
70. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.
Galanis E; Wu W; Cloughesy T; Lamborn K; Mann B; Wen PY; Reardon DA; Wick W; Macdonald D; Armstrong TS; Weller M; Vogelbaum M; Colman H; Sargent DJ; van den Bent MJ; Gilbert M; Chang S
Lancet Oncol; 2012 May; 13(5):e196-204. PubMed ID: 22554547
[TBL] [Abstract][Full Text] [Related]
71. [Recommendations for the organ donation from patients with brain or medullary primitive tumors on behalf of the Association of the Neuro-oncologists of French Expression (ANOCEF) and the Club of Neuro-oncology of the French Society of Neurosurgery].
Frappaz D; Le Rhun E; Dagain A; Averland B; Bauchet L; Faure A; Guillaume C; Zouaoui S; Provot F; Vachiery F; Taillandier L; Hoang-Xuan K
Bull Cancer; 2017 Sep; 104(9):771-788. PubMed ID: 28549594
[TBL] [Abstract][Full Text] [Related]
72. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
73. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
[TBL] [Abstract][Full Text] [Related]
74. Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative.
Dirven L; Armstrong TS; Blakeley JO; Brown PD; Grant R; Jalali R; Leeper H; Mendoza T; Nayak L; Reijneveld JC; Rhun EL; Walbert T; Weller M; Wen PY; Taphoorn MJB
Lancet Oncol; 2018 Mar; 19(3):e173-e180. PubMed ID: 29508764
[TBL] [Abstract][Full Text] [Related]
75. Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook.
Abdalla G; Hammam A; Anjari M; D'Arco DF; Bisdas DS
BJR Open; 2020; 2(1):20200009. PubMed ID: 33178973
[TBL] [Abstract][Full Text] [Related]
76. RAPNO efforts in Brain Tumour Outcomes.
Virani QU; Javed Z; Shamim MS
J Pak Med Assoc; 2024 May; 74(5):1005-1006. PubMed ID: 38783459
[TBL] [Abstract][Full Text] [Related]
77. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Okada H; Weller M; Huang R; Finocchiaro G; Gilbert MR; Wick W; Ellingson BM; Hashimoto N; Pollack IF; Brandes AA; Franceschi E; Herold-Mende C; Nayak L; Panigrahy A; Pope WB; Prins R; Sampson JH; Wen PY; Reardon DA
Lancet Oncol; 2015 Nov; 16(15):e534-e542. PubMed ID: 26545842
[TBL] [Abstract][Full Text] [Related]
78. Top advances of the year: Neuro-oncology.
Barden MM; Omuro AM
Cancer; 2023 May; 129(10):1467-1472. PubMed ID: 36825454
[TBL] [Abstract][Full Text] [Related]
79. Foundations of Neuro-Oncology: A Multidisciplinary Approach.
Barbaro M; Fine HA; Magge RS
World Neurosurg; 2021 Jul; 151():392-401. PubMed ID: 33618043
[TBL] [Abstract][Full Text] [Related]
80. A comprehensive approach in high-grade glioma management: position statement from the Neuro-Oncology Scientific Club (NOSC), Shiraz, Iran.
Ansari M; Mosalaei A; Ahmadloo N; Rasekhi A; Geramizadeh B; Razmkon A; Anvari K; Afarid M; Dadras A; Nafarieh L; Mohammadianpanah M; Nasrolahi H; Hamedi SH; Omidvari S; Nami M
Ger Med Sci; 2017; 15():Doc05. PubMed ID: 28325997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
